Drug intelligence / Profile preview

AZR-PED-015

Development stage: Preclinical
Lead developer: Azura Ophthalmics
Modality: Small Molecules
Administration: Ophthalmic

Overview

AZR-PED-015 is an investigational therapeutic being developed by Azura Ophthalmics for the treatment of Pediatric Blepharokeratoconjunctivitis (PBKC). PBKC is a chronic inflammatory condition of the eyelid margins and ocular surface that can lead to permanent vision loss if untreated. While specific details on the active ingredient are limited, Azura's pipeline focuses on restoring meibomian gland function through keratolytic mechanisms to improve tear film stability and reduce ocular surface inflammation. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on AZR-PED-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZR-PED-015.

Explore the full profile